Distinguished in WT1-Related Wilms Tumor Syndromes

Zwi N. Berneman

Edegem, VLG, BE 
Distinguished in WT1-Related Wilms Tumor Syndromes
Edegem, VLG, BE 
OverviewLocationsClinical Research

Overview

Zwi Berneman practices in Edegem, Belgium. Berneman is rated as a Distinguished expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Their top areas of expertise are Wilms Tumor, WT1-Related Wilms Tumor Syndromes, Febrile Neutropenia, Bone Marrow Transplant, and Corneal Transplant.

Their clinical research consists of co-authoring 152 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article and participated in 1 clinical trial in the study of WT1-Related Wilms Tumor Syndromes.

Locations

Edegem, VLG 2650, Belgium
Other Locations
Antwerpen, VLG, Belgium
Wilrijk, VLG, Belgium
Universitair Ziekenhuis Leuven
Leuven, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2024
Intervention Type: Biological
Study Drug: Autologous WT1 mRNA-Electroporated Dendritic Cell Vaccine
Study Phase: Phase 2
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Enrollment Status: Unknown
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Daunorubicin, Cytarabine, Idarubicin, Etoposide
Study Phase: Phase 3
View 1 Less Clinical Trial

152 Total Publications

Physiological Oxygen Levels in the Microenvironment Program Ex Vivo-Generated Conventional Dendritic Cells Toward a Tolerogenic Phenotype.
Physiological Oxygen Levels in the Microenvironment Program Ex Vivo-Generated Conventional Dendritic Cells Toward a Tolerogenic Phenotype.
Journal: Cells
Published: April 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Berneman's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile